bullish
Innovent Biologics (信达生物) IPO: Pricing the PD-1 and Biosimilars Competition (Part 2)
596 Views10 Oct 2018 11:05
Innovent Biologics, a leading biologics company in China, is raising up to USD 500 million to list in Hong Kong. In our previous insight (link...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Junshi Bioscience (君实医药) IPO: Early in Application but Behind in Key Indications (Part 1)12 Nov 2018
- Innovent Biologics (信达生物) Post IPO: Hit Our TP, What's Next?01 Nov 2018
- Innovent Biologics (信达生物) IPO: Limited Upside Despite Strong Cornerstones (Part 3)16 Oct 2018
- Innovent Biologics (信达生物) IPO: A Major PD-1 MAb Competitor Might Have Just Emerged (Part 1)13 Sep 2018
x